The global autologous stem cell and non-stem cell based therapy market is growing significantly due to high incidences of cancer and cardiovascular diseases, and presence of large number of patients requiring transplantation. The lack of service providers in the autologous stem cell market, and the massive unexplored autologous stem cell and non-stem cell based therapy market in the emerging economies, are creating ample growth opportunities for the global autologous stem cell and non-stem cell based therapy market. The advanced research and development activities and new product developments by the major players are supporting the demand for cost effective and efficient autologous stem cell and non-stem cell based therapy platforms.
The usage of multipotent stromal cell (mesenchymal stem cell) transplantation in multiple sclerosis is a trend, in the global autologous stem cell and non-stem cell based therapy market. In autologous stem cell and non-stem cell based therapy, an individual’s stem or non-stem cells are cultured outside the body and then transferred back into the body. The autologous cellular therapies do not require separate donor, instead it utilizes stem or non-stem cells from the individual who needs treatment for a particular disease. The U.S. Food and Drug Administration (FDA) defined the autologous use as “the implantation, transplantation, infusion, or transfer of human cells or tissue back into the individual, from whom the cells or tissue were recovered”. These cells are recovered mostly from the bone marrow or blood of the individual. Autologous cell therapy has better clinical results, and reduced rejection rate. The conventional treatment procedures with synthetic or allogenic materials have several disadvantages, such as abscess formation, foreign body granuloma formulation, and allergic reactions; however, the autologous stem cell and non-stem cell based therapy has overcome these limitations with better results.
The autologous stem cell and non-stem cell based therapy market is categorized as autoimmune diseases, cancer, neurodegenerative diseases, infectious diseases, and others.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/autologous-stem-cell-and-non-stem-cell-based-therapy-market/toc-sample
Some of the major players operating in the global autologous stem cell and non-stem cell based therapy market are Fibrocell Science Inc., BrainStorm Cell Therapeutics Inc., Vericel Corporation, Dendreon Corporation, Lion Biotechnologies, Genzyme Corporation, Regeneus Ltd., Caladrius, and Opexa Therapeutics Inc.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)